Uncategorized
Aerie completes enrollment in second phase 3 registration trial of Rhopressa
Aerie Pharmaceuticals completed enrollment in a second phase 3 registration trial of Rhopressa, according to a press release.Rocket 2 will measure efficacy over 3 months and safety over 1 year of Rhopressa, a once-daily eye drop that may lower IOP in patients with glaucoma or ocular hypertension. The primary efficacy endpoint is to show non-inferiority of IOP lowering for Rhopressa compared with timolol.